← Back to Screener
ArriVent BioPharma, Inc. Common Stock (AVBP)
Price$30.35
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)24.38%
Price vs S&P 500 (4W)2.89%
VGM Score80.03
Market Capitalization$1.41B
All Metrics
Book Value / Share (Quarterly)$7.15
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.97
Price vs S&P 500 (YTD)42.69%
EPS (TTM)$-3.52
10-Day Avg Trading Volume0.74M
EPS Excl Extra (TTM)$-3.52
EPS (Annual)$-4.32
ROI (Annual)-54.13%
Cash / Share (Quarterly)$7.20
ROA (Last FY)-49.92%
EBITD / Share (TTM)$-3.80
ROE (5Y Avg)-55.51%
Cash Flow / Share (Annual)$-3.78
P/B Ratio4.36x
P/B Ratio (Quarterly)3.15x
Net Income / Employee (Annual)$-2,159,800
ROA (TTM)-45.44%
EPS Incl Extra (Annual)$-4.32
Current Ratio (Annual)12.83x
Quick Ratio (Quarterly)13.93x
3-Month Avg Trading Volume0.52M
52-Week Price Return29.31%
Revenue / Employee (TTM)$0
52-Week High$33.62
EPS Excl Extra (Annual)$-4.32
26-Week Price Return32.30%
Quick Ratio (Annual)12.83x
13-Week Price Return20.20%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)13.95x
Enterprise Value$1.35B
Revenue / Employee (Annual)$0
Cash / Share (Annual)$7.37
3-Month Return Std Dev63.59%
Net Income / Employee (TTM)$-1,886,200
ROE (Last FY)-54.13%
EPS Basic Excl Extra (Annual)$-4.32
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.52
ROI (TTM)-48.98%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)4.95%
Year-to-Date Return50.84%
5-Day Price Return-1.08%
EPS Normalized (Annual)$-4.32
ROA (5Y Avg)-52.36%
Month-to-Date Return0.26%
EBITD / Share (Annual)$-4.62
ROI (5Y Avg)-55.51%
EPS Basic Excl Extra (TTM)$-3.52
P/B Ratio (Annual)2.70x
Book Value / Share (Annual)$7.24
Price vs S&P 500 (13W)11.94%
Beta1.08x
Revenue / Share (TTM)$0.00
ROE (TTM)-48.98%
52-Week Low$16.10
mGradeA
vgmGradeA
Show chart for
Earnings Surprise History
Q1 26-0.96est. -0.91
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.32
4.32
4.32
4.32
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AVBPArriVent BioPharma, Inc. Common Stock | — | — | A | $30.35 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
ArriVent BioPharma is a clinical-stage biopharmaceutical company developing differentiated cancer therapeutics with an initial focus on solid tumors. The company's lead candidate, furmonertinib, is in clinical development, supported by a pipeline that includes next-generation antibody-drug conjugates designed to address unmet oncology needs.